Assignee
CRISPR THERAPEUTICS AG
CH·83 granted patents·102 pending applications·268 citations·filing 2014–2025
Top patents by PatentIndex Score
185 records- 0198US11191783B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted Dec 7, 2021·6 cites·19 claims
- 0298US11166985B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted Nov 9, 2021·10 cites·14 claims
- 0398US11135247B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted Oct 5, 2021·6 cites·20 claims
- 0498US11071755B1Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted Jul 27, 2021·7 cites·24 claims
- 0598US11013767B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted May 25, 2021·5 cites·13 claims
- 0698US11008586B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2020·Granted May 18, 2021·10 cites·25 claims
- 0798US10865424B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2020·Granted Dec 15, 2020·18 cites·16 claims
- 0898US10736919B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2019·Granted Aug 11, 2020·13 cites·11 claims
- 0997US11434505B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2021·Granted Sep 6, 2022·6 cites·28 claims
- 1097US11433103B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2021·Granted Sep 6, 2022·6 cites·22 claims
- 1197US11207351B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2021·Granted Dec 28, 2021·3 cites·20 claims
- 1297US11180776B1Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2021·Granted Nov 23, 2021·6 cites·27 claims
- 1397US11118195B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2020·Granted Sep 14, 2021·9 cites·26 claims
- 1497US11116797B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2020·Granted Sep 14, 2021·9 cites·19 claims
- 1597US11118196B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2020·Granted Sep 14, 2021·9 cites·25 claims
- 1697US11104918B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2020·Granted Aug 31, 2021·9 cites·28 claims
- 1797US11008587B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2020·Granted May 18, 2021·9 cites·16 claims
- 1897US10881689B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2019·Granted Jan 5, 2021·7 cites·29 claims
- 1997US10857184B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2019·Granted Dec 8, 2020·9 cites·7 claims
- 2097US10729725B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2019·Granted Aug 4, 2020·7 cites·29 claims
- 2197US10724052B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2019·Granted Jul 28, 2020·21 cites·16 claims
- 2296US12427170B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2022·Granted Sep 30, 2025·2 cites·29 claims
- 2396US12365915B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2021·Granted Jul 22, 2025·2 cites·19 claims
- 2496US11578309B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2021·Granted Feb 14, 2023·7 cites·16 claims
- 2596US11566230B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2021·Granted Jan 31, 2023·9 cites·22 claims
- 2696US11459372B2Gene-edited natural killer cellsCRISPR THERAPEUTICS AG·Filed 2021·Granted Oct 4, 2022·3 cites·26 claims
- 2795US11298378B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2021·Granted Apr 12, 2022·2 cites·29 claims
- 2895US11202802B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2021·Granted Dec 21, 2021·2 cites·19 claims
- 2994US11559588B2Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Granted Jan 24, 2023·12 cites·18 claims
- 3094US11254912B2Methods and compositions for treating cancerCRISPR THERAPEUTICS AG·Filed 2021·Granted Feb 22, 2022·5 cites·14 claims
- 3193US11497773B2Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistenceCRISPR THERAPEUTICS AG·Filed 2021·Granted Nov 15, 2022·2 cites·20 claims
- 3293US11471491B1Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2021·Granted Oct 18, 2022·1 cites·18 claims
- 3392US11649438B2Methods and compositions for treating cancerCRISPR THERAPEUTICS AG·Filed 2021·Granted May 16, 2023·2 cites·18 claims
- 3492US11591381B2Gene-edited natural killer cellsCRISPR THERAPEUTICS AG·Filed 2021·Granted Feb 28, 2023·2 cites·27 claims
- 3591US12122998B2Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)CRISPR THERAPEUTICS AG·Filed 2021·Granted Oct 22, 2024·2 cites·22 claims
- 3690US12378572B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2019·Granted Aug 5, 2025·2 cites·17 claims
- 3790US11529427B2Gene editing for hemophilia A with improved factor VIII expressionCRISPR THERAPEUTICS AG·Filed 2020·Granted Dec 20, 2022·2 cites·20 claims
- 3889US11679130B2Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistenceCRISPR THERAPEUTICS AG·Filed 2021·Granted Jun 20, 2023·1 cites·29 claims
- 3989US11622977B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2018·Granted Apr 11, 2023·1 cites·25 claims
- 4089US11072792B2Materials and methods for treatment of usher syndrome type 2ACRISPR THERAPEUTICS AG·Filed 2020·Granted Jul 27, 2021·2 cites·16 claims
- 4188US11926676B2Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK7) and immune cells expressing suchCRISPR THERAPEUTICS AG·Filed 2021·Granted Mar 12, 2024·1 cites·30 claims
- 4288US11118177B2Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)CRISPR THERAPEUTICS AG·Filed 2020·Granted Sep 14, 2021·3 cites·2 claims
- 4388US2023302053A1Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 4487US12584144B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2023·Granted Mar 24, 2026·0 cites·20 claims
- 4587US12577582B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2023·Granted Mar 17, 2026·0 cites·19 claims
- 4687US10662425B2Materials and methods for treatment of autosomal dominant retinitis pigmentosaCRISPR THERAPEUTICS AG·Filed 2018·Granted May 26, 2020·3 cites·30 claims
- 4786US12215316B2Materials and methods for treatment of usher syndrome type 2ACRISPR THERAPEUTICS AG·Filed 2021·Granted Feb 4, 2025·1 cites·7 claims
- 4886US11332760B2Compositions and methods for genomic editing by insertion of donor polynucleotidesCRISPR THERAPEUTICS AG·Filed 2021·Granted May 17, 2022·2 cites·9 claims
- 4984US12559726B2Universal donor cellsCRISPR THERAPEUTICS AG·Filed 2023·Granted Feb 24, 2026·0 cites·20 claims
- 5084US11958908B2Compositions and methods for the depletion of CD117+ cellsCRISPR THERAPEUTICS AG·Filed 2020·Granted Apr 16, 2024·1 cites·26 claims
Showing the top 50 of 185 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when CRISPR THERAPEUTICS AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →